Individuals are now pursuing legal action against Novo Nordisk, the maker of Ozempic (semaglutide), alleging that the drug may cause significant and unexpected side effects. The primary issues highlighted in these lawsuits include gastroparesis, a condition that impairs normal stomach function, and vision loss linked to damage of the optic nerve. Claimants argue that the manufacturer failed to provide adequate warnings about these potential risks, leaving patients vulnerable to serious and potentially life-altering harm.

Start your free claim review

Ozempic Lawsuit Guide: Who Qualifies, Reported Injuries, Settlement Info & How to File

This guide covers eligibility for an Ozempic-related injury claim, outlines the main health complications involved, highlights the evidence that can support a case, discusses factors that may influence settlements, provides the latest lawsuit updates, and explains the steps of the legal process.

Eligibility for Filing an Ozempic Lawsuit

• Took Ozempic (semaglutide) for diabetes management or weight loss
• Subsequently developed gastroparesis (delayed or paralyzed stomach) or vision loss linked to optic nerve damage
• Suffered lasting health issues, required hospitalization, or experienced permanent disability

See if you qualify — free & confidential.

Health Risks from Ozempic: Gastroparesis and Vision Impairment

• Gastroparesis (Paralyzed Stomach): Plaintiffs claim that Ozempic can significantly slow stomach function, resulting in persistent nausea, vomiting, abdominal discomfort, malnutrition, and sometimes hospital stays. In severe instances, patients may need feeding tubes or surgical procedures.
• Vision Loss / Optic Nerve Damage: Legal claims also suggest a connection between Ozempic and optic nerve issues, potentially causing permanent vision loss. Affected individuals report sudden or gradual blindness, blurry vision, and other serious eye complications.

Key Evidence Needed for an Ozempic Lawsuit

• Prescription Records: Proof of Ozempic use, including dosage and treatment duration
• Medical Documentation: Records confirming a diagnosis of gastroparesis or optic nerve damage
• Hospital & Surgery Reports: Documentation of hospital stays or surgical procedures related to gastrointestinal issues
• Eye Care Records: Ophthalmology reports supporting vision loss claims
• Evidence of Impact: Documentation of lost income, daily activity limitations, or long-term disability

Ozempic Lawsuit Settlements and Influencing Factors

Because the legal proceedings are still active, there is currently no nationwide Ozempic settlement. Elements that could affect the value of an individual case include:

• Nature of the Injury: Whether the harm involves gastroparesis or permanent vision impairment
• Seriousness of the Condition: Extent of hospital stays, surgeries, or total vision loss
• Liability Evidence: Strength of proof showing the manufacturer failed to provide adequate warnings
• Court & Jury Factors: Certain jurisdictions and juries may award higher compensation in pharmaceutical cases

*For informational purposes only; actual settlement results depend on the specifics of each case and the applicable jurisdiction.

Latest Ozempic Lawsuit Developments – December 2025

• November 11, 2025: The Ozempic/GLP-1 MDL now includes 2,914 pending cases, up by 800 since August 1, averaging around 200 new filings per month.
• September 30, 2025: A California woman filed a Wegovy lawsuit citing serious gastrointestinal injuries, such as ileus and gastroparesis, alleging Novo Nordisk failed to properly warn about risks while promoting the drug as safe for long-term weight loss.
• September 21, 2025: Plaintiffs begin focusing on sudden vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION), shifting attention from gastroparesis. The severity of these injuries and existing regulatory warnings make these claims stronger in court.
• September 17, 2025: Proposed Master and Short Form Complaints introduced in the MDL to streamline case filings and organization. Defendants have 60 days to respond, with motions to dismiss tightly regulated.
• September 11, 2025: Eli Lilly requests an NAION-focused MDL to consolidate vision loss cases across Ozempic, Mounjaro, Trulicity, and Wegovy, asking Judge Karen Marston—already overseeing GI injury cases—to manage the new docket.
• September 6, 2025: Judge Marston sets new criteria, confirming the litigation will concentrate on NAION-related vision injuries and gastroparesis confirmed by diagnostic tests.
• September 5, 2025: FDA approves suppliers for compounded GLP-1 drugs, limiting imports from unauthorized manufacturers.
• September 1, 2025: FDA clears Wegovy for treating fatty liver disease (MASH), making it the first GLP-1 therapy approved for this condition.
• August 15, 2025: Judge Marston narrows gastroparesis claims to those with objective test results, but allows labeling, warranty, and fraud-related allegations against Novo Nordisk and Eli Lilly to proceed.
• Early 2025: Federal lawsuits continue to expand as patients allege Ozempic causes gastroparesis and vision loss, with judges reviewing requests for case coordination.
• 2024: Medical research links GLP-1 drugs, including Ozempic, to severe delayed gastric emptying and optic nerve damage.
• 2023: Initial filings allege permanent injuries like stomach paralysis and vision loss, focusing on claims that patients were not adequately warned of these risks.

This section is updated monthly to reflect ongoing MDL activity.

Understanding the Ozempic Lawsuit Process

1. Free Case Review: Submit your prescription records and relevant medical documentation.
2. Case Investigation: Attorneys examine the evidence and may consult medical specialists in gastroenterology or ophthalmology.
3. Filing the Claim: Lawsuits can be filed individually or consolidated within federal MDL proceedings.
4. Discovery & Negotiation: Exchange of medical records and expert analyses occurs while exploring settlement or mediation options.
5. Resolution: Cases may conclude through settlement, mediation, or trial, depending on the specifics of each claim.

Start your free claim review — no upfront fees.

Sources

• National Institutes of Health (NIH): Research on GLP-1 agonists and delayed gastric emptying
• American Academy of Ophthalmology (AAO): Reports linking GLP-1 drugs to vision loss
• New England Journal of Medicine (NEJM): Clinical studies on semaglutide

Get a Free Case Review

Answer a few questions to see if you qualify. All information you provide is kept confidential, and there are no upfront costs.